international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
decreased. Inventories decreased by 639.0 MB, representing a decrease of 40.5%. This is because during Q3–2021, many large-scale projects have been delivered which their projects value are greater than the
37.11%, decreased from 61.56% in 2Q2021 due to the increase in employee-related costs to support the planned increase of scale and scope of services to be provided by the Company and clients in mobile
meetings and conducting public hearings. (In 2012, the SEC held 22 public consultations via its website.) In case of a high impact regulation, a large-scale seminar may be necessary. Moreover, the proposed
meetings and conducting public hearings. (In 2012, the SEC held 22 public consultations via its website.) In case of a high impact regulation, a large-scale seminar may be necessary. Moreover, the proposed
directors successfully executed a turn-around, and the company was able to invest in its drug pipeline again. However, it had entered a stage when it was failing to reach critical CRITERIA FOR “HEAVY
efficiency of the new stores launched in the year 2017 to benefit from economies of scale. In the first quarter 2018, the Company had total revenue of 15,900.33 million Baht, an increase of 627.77 million Baht